Track market-moving stories before they get noisy

Posted by Defense World Staff on Apr 4th, 2026

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $110.00.

Several brokerages recently weighed in on GPCR. The Goldman Sachs Group upgraded Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Guggenheim upped their price target on Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, March 17th. HC Wainwright cut their price objective on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 16th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th.

Get Our Latest Stock Analysis on Structure Therapeutics

Structure Therapeutics Stock Performance Shares of GPCR stock opened at $53.48 on Friday. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90. The stock has a market cap of $3.79 billion, a price-to-earnings ratio of -67.70 and a beta of -1.17. The company’s 50-day moving average price is $64.67 and its 200-day moving average price is $52.40.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, equities research analysts predict that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics Several large investors have recently made changes to their positions in the stock. CWM LLC lifted its stake in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Structure Therapeutics by 3.6% in the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after buying an additional 320 shares during the period. State of Wyoming raised its holdings in shares of Structure Therapeutics by 29.7% in the 4th quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after buying an additional 403 shares during the period. PNC Financial Services Group Inc. lifted its stake in Structure Therapeutics by 9.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after acquiring an additional 413 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Structure Therapeutics by 4.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after acquiring an additional 444 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics (Get Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

Read More Five stocks we like better than Structure Therapeutics

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDHT Holdings, Inc. (NYSE:DHT) Receives Average Rating of “Moderate Buy” from Analysts

NEXT HEADLINE »American National Bank & Trust Has $2.71 Million Stock Holdings in Duke Energy Corporation $DUK

Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario.

Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can get in on the action by targeting companies that manufacture these powerful drugs.

It's a mistake to assume that all sales of GLP-1 drugs will be limited to the major products Ozempic or Wegovy, both manufactured by pharma giant Novo Nordisk A/S NYSE: NVO. The demand in this relatively new space is so great that a growing number of alternatives are quickly emerging, despite the seeming dominance of a few major players. Below, we'll look at a standalone, lesser-known biotech developer with a promising alternative in the works, as well as two exchange-traded funds (ETFs) that can give broad and diversified exposure to the whole industry at once.

Get OZEM alerts:

A Pivot Toward GLP-1 Drugs Could Be Transformational for Structure TherapeuticsStructure Therapeutics NASDAQ: GPCR is a biotechnology company developing drugs focused on G protein-coupled receptors, or GPCRs. The firm has traditionally targeted new treatments for metabolic and inflammatory diseases like fibrosis or nonalcoholic steatohepatitis.

Structure Therapeutics Today

GPCR

Structure Therapeutics

$43.30 +1.77 (+4.26%)

As of 06/11/2026 04:00 PM Eastern

52-Week Range$15.80▼

$94.90Price Target$106.75

The company has more recently followed the trend toward GLP-1 drugs as well, and its aleniglipron has recently demonstrated 16.3% weight loss, adjusted for certain trial factors, and could beat out some competitors in terms of safety and manufacturing costs.

Though Structure is not currently profitable, it does have a solid cash position of about $1.4 billion. This should give it ample runway over the next several quarters as it continues to develop aleniglipron, with the drug candidate moving toward a critical Phase 3 trial.

Analysts have flagged Structure for its strong potential based on the promise of aleniglipron. Ratings for GPCR stock include 15 out of 18 ratings of Buy or equivalent. Shares have been hit fairly hard so far this year, declining by 20% in the midst of a challenging set of external factors, but bullishness still wins the day across Wall Street: with a consensus price target of $110, Structure's share price could more than double.

The First GLP-1 Agonist ETF Is Building a Track Record of SuccessInvestors should know that there is massive potential in the GLP-1 space thanks to the recent proliferation of ETFs dedicated to this investment strategy. The Roundhill GLP-1 & Weight Loss ETF NASDAQ: OZEM was an early leader in this space, launching in mid-2024. The fund takes a fairly focused approach, targeting about two dozen pharmaceutical companies positioned to benefit from the growth of the GLP-1 agonist industry.

Roundhill GLP-1 & Weight Loss ETF Today

OZEM

Roundhill GLP-1 & Weight Loss ETF

$30.85 +0.96 (+3.21%)

As of 06/11/2026 03:56 PM Eastern

52-Week Range$23.22▼

$37.15Assets Under Management$47.37 million

Novo Nordisk and major rival Eli Lilly & Co. NYSE: LLY feature prominently, accounting for nearly 30% of the portfolio in total. The fund's basket is fairly broad, though, and includes a number of domestic and international names to provide substantial geographical diversification.

Crucially, the fund provides exposure not only to large companies involved in producing or selling GLP-1 therapeutics, but also to those creating other weight loss enablers and even to companies supporting the supply chain vital to production.

As an actively managed fund, OZEM has an expense ratio of 0.59%; this may be high in comparison with ETFs overall but is actually quite competitive relative to other active funds. The fund is quite niche, so it has a modest asset base of some $52 million and relatively low trading volumes. Still, it is up an impressive 45% in the last year, rewarding those investors willing to buy and hold. A modest dividend serves as an added bonus.

Another GLP-1 ETF With a Passive ApproachAn alternative in the GLP-1 ETF space is the Amplify Weight Loss Drug & Treatment ETF NYSEARCA: THNR. In many ways THNR is quite similar to OZEM: this fund also carries an annual fee of 0.59% and tracks roughly two dozen pharma names connected to the GLP-1 agonist market. It also weighs Novo Nordisk and Eli Lilly heavily, although these two companies combine to make up just around a quarter of the portfolio, so there is a bit more room in the case of THNR for access to other companies.

Amplify Weight Loss Drug & Treatment ETF Today

THNR

Amplify Weight Loss Drug & Treatment ETF

$24.53 +0.54 (+2.25%)

As of 06/11/2026 04:10 PM Eastern

52-Week Range$21.70▼

$27.28Assets Under Management$4.08 million

A big difference, though, is that THNR is not an actively managed fund. Rather, it tracks an index of companies in the GLP-1 industry. Its weighting is determined by float-adjusted market cap, and its portfolio is influenced by factors such as market cap weighting and trading volume.

While the basket is rebalanced just four times a year, some investors may find that this passive reflection of the market is more suitable for their interests than an active management approach.

On the other hand, THNR's asset base is tiny, at just $4 million, and its trading volume matches. The fund has returned about 30% in the last year—still roughly on par with the broader market, but well below OZEM.

Should You Invest $1,000 in Roundhill GLP-1 & Weight Loss ETF Right Now?Before you consider Roundhill GLP-1 & Weight Loss ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roundhill GLP-1 & Weight Loss ETF wasn't on the list.

While Roundhill GLP-1 & Weight Loss ETF currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Reported positive results from aleniglipron Phase 2 ACCESS II study 
with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs
at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs

Data from ACCESS OLE expected in Q3 2026;
Data from the Body Composition and Type 2 Diabetes/Obesity data expected in Q4 2026

Positive end-of-Phase 2 feedback received from FDA;
aleniglipron Phase 3 initiation on track for Q3 2026

Initial data from Phase 1 single ascending dose (SAD) study of
oral small molecule amylin receptor agonist ACCG-2671 and
initiation of multiple ascending dose (MAD) study expected in Q3 2026;
Phase 1 initiation of second oral amylin candidate ACCG-3535 expected in Q4 2026

Aleniglipron, amylin and combination data to be presented
at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026

Cash, cash equivalents and short-term investments of $1.5 billion as of March 31, 2026, expected to provide cash runway through the end of 2028

SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

“With positive end of Phase 2 feedback received from the FDA for aleniglipron, we are well positioned to start our Phase 3 registrational program for chronic weight management in the third quarter,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “We are also looking forward to our aleniglipron presentation along with presentations on our oral amylin and GLP-1 combination program at the upcoming ADA meeting. With our Phase 1 clinical data for our oral amylin candidate ACCG-2671 anticipated in the third quarter and additional aleniglipron data later this year, our broad portfolio positions us well in the evolving landscape that we believe will favor more accessible oral small molecules, extended maintenance treatment, and fixed dose oral combinations for specific patient populations and expanded indications.”

Recent and Upcoming Milestones

Aleniglipron - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight

In March 2026, the Company reported data from the aleniglipron clinical program included 44-week topline data from the Phase 2 ACCESS II study, as well as interim data from body composition study and Phase 2b ACCESS open label extension (OLE) study.

The Phase 2 ACCESS II study demonstrated a placebo-adjusted mean weight loss of 16.3% (39 Ibs; p<0.0001) at the 180 mg dose and 16.0% (37 Ibs; p<0.0001) at the 240 mg dose at 44 weeks.The ongoing ACCESS OLE study achieved continued weight loss up to 16.2% (40.5 lbs) observed with 120 mg dose at 56 weeks.No weight loss plateau was observed in any of the studies. Data from the ACCESS, ACCESS II, Body Composition, and the ACCESS OLE studies provide a strong foundation for the decision to advance aleniglipron into Phase 3 clinical development. The Company expects to report topline results from the ACCESS OLE and Body Composition studies in Q3 and Q4 2026, respectively.

The Company received positive end-of-Phase 2 feedback from the U.S. Food and Drug Administration (FDA) and clear guidance on the Phase 3 program with a starting titration dose of 2.5 mg and the intent to evaluate multiple doses. The Company anticipates initiating the Phase 3 program in Q3 2026.

The Company is also conducting supplementary studies to enhance the competitive profile of aleniglipron, including:

Ongoing study of ACCESS OLE to evaluate the tolerability profile of the dosing regimen starting at the 2.5 mg dose for those previously on placebo and to collect up to 72 weeks of data exposure to aleniglipron, including 180 mg dose. Data are expected in Q3 2026.Ongoing Body Composition study to assess the effect of aleniglipron on body fat loss over a 44-week evaluation period, which includes a 28-week titration period and a starting dose of 2.5 mg and target dose of 180 mg of aleniglipron. These data will be used to inform the size of a sub study into the Phase 3 program. Data are expected in Q4 2026.Ongoing 30-week study in patients with type 2 diabetes mellitus (T2DM) with obesity/overweight and a starting dose of 2.5 mg and target dose of 180 mg of aleniglipron to evaluate the potential for including participants with T2DM in the Phase 3 obesity program. Data are expected in Q4 2026.Ongoing SWITCH study to assess the transition or switching from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance. This study assesses different aleniglipron starting doses and weight loss maintenance over 12 weeks. Data are expected in Q4 2026. Oral Small Molecule Amylin Receptor Agonists

In December 2025, the Company advanced ACCG-2671 into a Phase 1 clinical study as the industry’s most advanced oral small molecule amylin therapy for the treatment of obesity. ACCG-2671 is being evaluated in an ongoing single ascending dose (SAD) study to measure safety, tolerability, pharmacokinetics, and food-effect of single ascending doses in healthy adult participants with data anticipated in 2H 2026. In addition, the Company expects to initiate a multiple ascending dose (MAD) study in Q3 2026.In November 2025, the Company declared a second oral small molecule dual amylin calcitonin receptor agonist development candidate, ACCG-3535. ACCG-3535, which is a unique chemical structure compared to ACCG-2671, demonstrated robust food intake suppression and significant, dose-dependent body weight reduction as a monotherapy in diet-induced obese rats. Combination therapy with semaglutide (both concurrently and as a subsequent add-on to semaglutide) resulted in superior weight loss compared to semaglutide or ACCG-3535 monotherapy. The Company expects to initiate a Phase 1 clinical study of ACCG-3535 in Q4 2026. Multiple presentations at ADA, taking place from June 5–8, 2026

Details of the presentations are as follows:

Title: ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with Obesity and Overweight
Session: Oral Presentations - Human Studies in Obesity Treatment: Emerging Therapeutic Options and Strategies for Decision-Making (1032-OR)
Speaker: Julio Rosenstock, MD, University of Texas Southwestern Medical Center
Date: Friday, June 5: 12:45 p.m. – 1:00 p.m. CT

Title: Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial
Session: General Poster Session (2637-P)
Date: Monday, June 8: 12:30 p.m. – 1:30 p.m. CT

Title: Exploring a Lower Starting Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials
Session: Late Breaking Poster Session (3101-LB)
Date: Sunday, June 7: 12:30 p.m. – 1:30 p.m. CT

Title: Combination Treatment of Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron and Small Molecule Amylin Receptor Agonist ACCG-2671 Demonstrated Additional Weight Loss than Monotreatment in Obese NHPs
Session: Late Breaking Poster Session (3061-LB)
Date: Sunday, June 7: 12:30 p.m. – 1:30 p.m. CT

Title: Comparison of Conditioned Taste Avoidance Profiles between GLP-1 Peptides, Amylin Peptides, and Small Molecule Amylin Receptor Agonists
Session: Late Breaking Poster Session (3062-LB)
Date: Sunday, June 7: 12:30 p.m. – 1:30 p.m. CT

Additional information about the ADA 2026 Scientific Sessions is available at the ADA meeting website (American Diabetes Association).

First Quarter 2026 Financial Highlights

Cash Position: Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026. The Company received $100.0 million in the first quarter of 2026, consisting of an upfront license fee for certain patents that cover a class of oral GLP-1 receptor agonists that is different from aleniglipron. The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones through the end of 2028. This includes costs related to the ongoing aleniglipron ACCESS OLE, ACCESS II extension study, the supplementary studies, and Phase 3 registrational studies in chronic weight management, but excludes additional costs related to pre-commercialization activities including commercial manufacturing.

Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2026 were $66.5 million, as compared to $42.9 million for the same period in 2025. The increase in R&D expenses was primarily due to increases related to clinical trial costs, preclinical research and development expenses and employee expenses (primarily due to an increase in personnel) to support the advancement of our GLP-1R franchise including aleniglipron.

General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2026 were $22.9 million, as compared to $13.4 million for the same period in 2025. The increase in G&A expenses was primarily due to increases in employee expenses as we expanded our infrastructure to drive and support the growth in our operations and professional services.

Net Loss: Net loss for the first quarter of 2026 totaled $76.0 million, with non-cash share-based compensation expense of $11.6 million, compared to $46.8 million for the same period in 2025 with non-cash share-based compensation expense of $5.9 million.

About Aleniglipron and Structure Therapeutics’ Oral Metabolic Franchise
Aleniglipron (GSBR-1290) is an investigational orally-available, small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of obesity and T2DM. Through Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed to be a biased G Protein-Coupled Receptor (GPCR) agonist, which selectively activates the G-protein signaling pathway. Beyond aleniglipron, Structure Therapeutics is developing next generation oral small molecules including amylin receptor agonists (ACCG-2671 and ACCG-3535), and other combination GLP-1 receptor agonists candidates targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon and apelin receptors.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; the expected timing of ACCESS OLE and Body Composition studies data readouts; the planned initiation of the aleniglipron Phase 3 study and the timing thereof; the expected timing of initial data from the Phase 1 study of ACCG-2671; the planned initiation of the ACCG-3535 Phase 1 study and the timing thereof; the belief that data to date from the ACCESS, ACCESS II, Body Composition, and the ACCESS OLE studies support and inform aleniglipron advancement into Phase 3 clinical development; the Company’s anticipated cash runway and uses of cash; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron; any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials. In addition, when or if used in this press release, the words and phrases "anticipated," "believe," "expect," "potential," "to be," "will," and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to topline results that the Company reports are based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; the preliminary nature of the results due to the length of the study and sample size and the results from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and completion of the Company's planned Phase 3 clinical program and other clinical studies; disruptions to the operations of the FDA or other U.S. governmental agencies or comparable foreign regulatory authorities caused by funding shortages, leadership changes, or staffing reductions; the Company's ability to advance aleniglipron, ACCG-2671, LTSE-2578, ACCG-3535, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company's therapeutic candidates; competitive products or approaches limiting the commercial value of the Company's product candidates; the timing and results of preclinical and clinical studies; the Company's ability to fund development activities and achieve development goals; the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control; general geopolitical and macroeconomic conditions, including as a result of tariffs and various global conflicts; the Company's ability to protect its intellectual property; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
[email protected]

Jun Yoon
Structure Therapeutics Inc.
[email protected]

Media:
Dan Budwick
1AB
[email protected]

 STRUCTURE THERAPEUTICS INC.Condensed Consolidated Statements of Operations(unaudited)(In thousands)         THREE MONTHS ENDED   MARCH 31,     2026
    2025
Operating expenses:        Research and development $66,507  $42,867 General and administrative  22,872   13,444 Total operating expenses  89,379   56,311 Loss from operations  (89,379)  (56,311)Interest and other income, net  13,601   9,576 Loss before provision for income taxes  (75,778)  (46,735)Provision for (benefit from) income taxes  190   98 Net loss $(75,968) $(46,833)                     Research and development $5,101  $2,699 General and administrative  6,538   3,219 Total share-based compensation $11,639  $5,918         STRUCTURE THERAPEUTICS INC.Condensed Consolidated Balance Sheet Data(unaudited)(In thousands)          MARCH 31,   DECEMBER 31,      2026   2025   Assets       Current assets:         Cash, cash equivalents and short-term investments $1,458,504 $1,446,197 Prepaid expenses and other current assets  32,094  124,106 Total current assets  1,490,598  1,570,303 Property and equipment, net  6,365  6,653 Operating right-of-use assets  5,606  6,245 Other non-current assets  5,555  717 Total assets $1,508,124 $1,583,918 Liabilities and shareholders’ equity         Current liabilities:         Accounts payable $7,822 $13,864 Accrued expenses and other current liabilities  46,553  46,543 Operating lease liabilities, current portion  2,609  2,878 Total current liabilities  56,984  63,285 Operating lease liabilities, net of current portion  3,183  3,609 Other non-current liabilities  863  647 Total liabilities  61,030  67,541 Total shareholders’ equity  1,447,094  1,516,377 Total liabilities and shareholders’ equity $1,508,124 $1,583,918         

Key Takeaways Lilly is advancing oral obesity pills and next-gen GLP-1 drugs to stay ahead in weight loss.LLY's retatrutide showed strong weight loss and osteoarthritis pain relief in phase III studies.Lilly is testing eloralintide and bimagrumab to expand beyond traditional GLP-1 therapies. Eli Lilly and Company (LLY - Free Report) is a leader in the fast-growing diabetes and obesity market, driven by its blockbuster tirzepatide-based drugs, Mounjaro and Zepbound. Tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), remains the foundation of Lilly’s obesity franchise. Beyond obesity and diabetes, Lilly is evaluating tirzepatide in several obesity-related conditions, such as obstructive sleep apnea (OSA), chronic kidney disease, fatty liver disease and cardiovascular conditions.

Mounjaro and Zepbound face strong competition from Novo Nordisk’s (NVO - Free Report) semaglutide medicines, Ozempic, for diabetes and Wegovy for obesity.

Though Lilly and Novo Nordisk presently dominate the market, they are making rapid progress in the development of more potent and convenient GLP-1 as well as non-GLP-1 based candidates in their clinical pipeline to beat future competition. The global obesity drug market is projected to grow dramatically, reaching nearly $95 billion by 2030 and potentially $125 billion by 2035, according to Goldman Sachs estimates, which means competition is inevitable.

Oral Obesity Drugs Could Be a Commercial Game-ChangerBoth Lilly and NVO have launched oral GLP-1 pills. Lilly’s Foundayo and Novo Nordisk’s Wegovy pill can prove to be commercial game-changers for the respective companies. Oral pills will be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Zepbound and Wegovy. Oral pills may significantly lower the treatment burden and potentially broaden patient adoption versus injections. Oral pills can also be manufactured at scale to meet global demand, which, in turn, can drive billions in additional sales. Both Lilly and Novo Nordisk said their oral pills witnessed strong launches.

Lilly expects to launch Foundayo in most international markets during 2027. For the type II diabetes indication, Lilly has filed regulatory applications for Foundayoin several countries, while it expects to file the same in the United States in late second quarter. In addition to obesity and diabetes, Lilly is evaluating Foundayo in six phase III studies for other diabetes and obesity-related diseases.

Retatrutide May Succeed Tirzepatide in Lilly’s PortfolioLilly is developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates. Its obesity and diabetes pipeline has therefore evolved from a traditional insulin and diabetes-drug portfolio into a comprehensive metabolic-disease platform.

A key candidate in its obesity pipeline is triple-acting incretin, retatrutide, being studied in type II diabetes and obesity, along with other indications like OSA, knee osteoarthritis, and chronic low back pain, in late-stage studies. Retatrutide represents a new generation of “triple-action” therapy as it targets three biological pathways — GLP-1, GIP and glucagon — whereas existing medicines mostly act on one or two biological pathways.

Data from a phase III study of retatrutide in obesity and knee osteoarthritis pain showed that the drug led to significant weight loss and substantial relief of osteoarthritis pain. Data from a phase III study in type II diabetes showed that retatrutide can achieve glycemic control comparable to tirzepatide, while providing additional weight loss.

Eloralintide and Bimagrumab Expand Lilly Beyond GLP-1 TherapiesAnother key candidate in Lilly’s diabetes/obesity pipeline is eloralintide, a selective amylin receptor agonist. Lilly is exploring eloralintide both alone and in combination with incretin therapies. Phase III studies are ongoing for obesity, OA knee pain and OSA. Lilly believes that eloralintide has the potential to be a great medicine for patients seeking a non-GLP-1-based mechanism due to tolerability issues.

Through its 2023 acquisition of Versanis, Lilly gained bimagrumab, an ActRII inhibitor being studied alone and in combination with tirzepatide to improve body composition by reducing fat while maintaining or increasing lean muscle mass. It is in phase II studies for obesity.

Competition Heating Up in the Obesity SpaceNovo Nordisk’s other novel candidate in its obesity pipeline is CagriSema, a once-weekly injection, which is a combination of cagrilintide (amylin analogue) and semaglutide (GLP-1). NVO has already filed a new drug application with the FDA seeking approval of CagriSema for obesity. Other key candidates are cagrilintide, a long-acting amylin analog in phase III, and amycretin, a single molecule combining GLP-1 + amylin, which is expected to enter phase III in 2026.

Several other companies, like Amgen, Viking Therapeutics (VKTX - Free Report) and Structure Therapeutics (GPCR - Free Report) are also making rapid progress in the development of more potent and convenient candidates in their clinical pipeline.

Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity.  Viking plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.

Structure Therapeutics’ phase II ACCESS study on its orally GLP-1 RA, aleniglipron, demonstrated significant weight loss across all doses. Structure Therapeutics expects to initiate the late-stage program of aleniglipron in obesity in the second half of 2026.

Amgen is developing MariTide, a GIPR/GLP-1 receptor, as a single dose in a convenient autoinjector device with a monthly and possibly less frequent dosing. This key feature differentiates it from Zepbound and Wegovy, which are weekly injections. Amgen has nine global phase III studies underway with MariTide in obesity, type II diabetes and other obesity-related conditions.

LLY’s Stock Price, Valuation and EstimatesLilly’s stock has declined 7.9% so far this year compared with the industry’s decrease of 4%.

Image Source: Zacks Investment Research

From a valuation standpoint, Lilly’s stock is expensive. Going by the price/earnings ratio, LLY’s shares currently trade at 25.46 forward earnings, much higher than 16.47 for the industry. However, LLY’s stock is trading below its 5-year mean of 34.57.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 has risen from $34.69 to $35.43 per share over the past 30 days, while that for 2027 has risen from $42.98 to $44.26 per share over the same timeframe.

Image Source: Zacks Investment Research

LLY’s Zacks RankLilly has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

HighVista Strategies sold 69,092 shares of Structure Therapeutics (GPCR +4.26%) in the first quarter, an estimated $4.73 million trade based on quarterly average pricing, per the May 15, 2026 SEC filing.

What happenedAccording to an SEC filing dated May 15, 2026, HighVista Strategies reduced its holding in Structure Therapeutics by 69,092 shares during the first quarter. The estimated transaction value was $4.73 million, calculated using the average closing price for the quarter. The position’s quarter-end value decreased by $7.45 million, a figure that incorporates both the share sale and market price fluctuations.

What else to knowThis was a sell; post-trade, the Structure Therapeutics stake represents 1.6491% of HighVista’s reportable U.S. equity AUMTop holdings after the filing:NYSEMKT:DBC: $30.61 million (8.5% of AUM)NASDAQ:ABVX: $12.61 million (3.5% of AUM)NASDAQ:PRAX: $8.48 million (2.3% of AUM)NASDAQ:COGT: $7.58 million (2.1% of AUM)NASDAQ:SYRE: $7.38 million (2.0% of AUM)As of May 14, 2026, shares of Structure Therapeutics were priced at $39.84, up about 60% over the past year and well outperforming the S&P 500’s roughly 25% gain in the same period.Company OverviewMetricValuePrice (as of market close 2026-05-14)$39.84Market Capitalization$2.8 billionNet Income (TTM)($141.2 million)One-Year Price Change60%Company SnapshotStructure Therapeutics develops oral therapeutics targeting chronic diseases, with lead candidate GSBR-1290 for type-2 diabetes and obesity, and additional pipeline assets for pulmonary and cardiovascular indications.The company operates a clinical-stage biopharmaceutical business model focused on proprietary research, development, and out-licensing or commercialization of novel small molecule drugs targeting G-protein-coupled receptors (GPCRs).It targets healthcare providers, biopharma partners, and patients with unmet medical needs in metabolic, pulmonary, and cardiovascular disease segments.Structure Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of innovative oral small molecule therapeutics for chronic diseases with significant unmet need. The company's strategy leverages expertise in GPCR biology to advance a pipeline of differentiated oral therapeutics for chronic diseases. With a focus on metabolic and pulmonary indications, Structure Therapeutics seeks to establish a competitive edge through proprietary drug design and a robust clinical development program.

What this transaction means for investorsStructure Therapeutics shares have climbed about 60% over the past year as investors piled into companies developing next-generation GLP-1 therapies, especially oral alternatives to injectable weight-loss drugs. With that kind of run, it doesn’t seem surprising for a fund to consider rebalancing.

For its part, the company has continued delivering strong clinical updates. Earlier this month, Structure reported Phase 2 data showing up to 16.3% placebo-adjusted weight loss at 44 weeks for oral obesity candidate aleniglipron, which management said compares favorably with injectable GLP-1 therapies. The company also said it received positive end-of-Phase 2 FDA feedback and remains on track to launch Phase 3 trials in the third quarter.

Separately, Structure ended March with roughly $1.5 billion in cash, cash equivalents, and short-term investments, which management says should fund operations through the end of 2028.

Ultimately, the key question is whether oral GLP-1 drugs can carve out a meaningful slice of a market currently dominated by injectable therapies. High expectations are already baked into many obesity stocks, but Structure’s growing clinical data package suggests the company remains one of the more serious contenders in the space.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Key Takeaways Mounjaro and Zepbound saw strong Q1 sales growth, fueled by robust demand despite lower pricing.New label expansions and indication approvals could further boost Mounjaro and Zepbound sales.Foundayo has reached over 20,000 U.S. patients and a launch is planned for most international markets in 2027. Eli Lilly (LLY - Free Report) has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its blockbuster GLP-1 therapies, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Both drugs include the same compound, tirzepatide, a dual GIP/GLP-1 RA. The GLP-1 segment is a very important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.

Despite a short time on the market, Mounjaro and Zepbound have become LLY’s key top-line drivers. Mounjaro is the market leader in new prescriptions among incretin analogs for T2D in both the United States and ex-U.S. markets. At the same time, Zepbound holds a leading market share in the branded obesity market, with nearly 70% of new prescriptions.

In the first quarter of 2026, Mounjaro recorded sales of $8.66 billion, up 125% year over year, while Zepbound’s sales were $4.16 billion, up 80% year over year, driven by increased demand, which offset the impact of lower pricing. The positive trend is expected to continue in 2026.

New indication approvals and ongoing label expansions could further boost sales of Eli Lilly’s Mounjaro and Zepbound. Last year, Zepbound gained FDA approval for obstructive sleep apnea in adults with obesity, while LLY has also filed for a cardiovascular indication based on positive late-stage data. Tirzepatide has also been approved for pediatric and adolescent T2D in the United States and the EU, with additional studies underway in type I diabetes and metabolic dysfunction-associated steatotic liver disease. Lilly is also supporting growth through lower-priced Zepbound vial doses, self-pay savings programs and expanded incretin manufacturing capacity.

Eli Lilly’s newly approved once-daily oral GLP-1 pill, Foundayo, has shown encouraging early launch momentum in obesity, with broad pharmacy availability, access through major telehealth platforms and commercial coverage from two of the three largest U.S. pharmacy benefit managers. More than 8,000 healthcare providers have prescribed the drug, while over 20,000 patients have received it so far, with most prescriptions coming from people new to GLP-1 therapy.

Lilly plans to launch Foundayo in most international markets in 2027 and is pursuing approvals for T2D in several countries, with a U.S. filing expected in late second-quarter 2026. Backed by consistent safety and efficacy data across seven phase III studies, Foundayo is being positioned as a key growth driver for Lilly in obesity, diabetes and related metabolic diseases.

LLY’s Peers in the Obesity SpaceEli Lilly and Novo Nordisk (NVO - Free Report) presently dominate the obesity market. Mounjaro and Zepbound directly compete with NVO’s semaglutide medicines, Ozempic for T2D and Wegovy for obesity. Like Eli Lilly, Novo Nordisk also generates a substantial portion of revenues from both drugs.

Novo Nordisk gained approval for an oral version of its obesity drug, Wegovy, in December 2025 and launched the pill in January 2026, giving it a first-mover advantage over Foundayo. However, Lilly may be able to close the gap quickly now that it has launched Foundayo. Also, Foundayo offers better patient convenience, as it can be taken at any time of day, with or without food. In contrast, NVO’s Wegovy pill must be taken on an empty stomach, followed by a 30-minute wait before eating. However, in terms of side effects, Wegovy has a slight edge, as it appears to have a more stable safety and tolerability profile than Foundayo, whose use is associated with some gastrointestinal side effects.

Smaller biotech firms, like Viking Therapeutics (VKTX - Free Report) and Structure Therapeutics (GPCR - Free Report) , are also advancing GLP-1–based therapies to challenge the incumbents. Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking Therapeutics plans to advance oral VK2735 into phase III development for obesity in the fourth quarter of 2026.

Structure Therapeutics’ phase II ACCESS study on its orally administered GLP-1 RA, aleniglipron, demonstrated significant weight loss across all doses. Structure Therapeutics expects to initiate the late-stage program of aleniglipron in obesity in the second half of 2026.

LLY’s Stock Price, Valuation and EstimatesShares of Eli Lilly have lost 5.2% year to date compared with the industry’s 0.7% decline. During the same time frame, the company has also underperformed the S&P 500 but outperformed the sector, as seen in the chart below.

LLY Stock Price MovementImage Source: Zacks Investment Research

From a valuation standpoint, LLY stock is expensive. Going by the price/earnings ratio, the company’s shares currently trade at 26.23 forward earnings, higher than 16.98 for the industry. However, the stock is trading below its five-year mean of 34.56.

LLY Stock ValuationImage Source: Zacks Investment Research

Estimates for Eli Lilly’s 2026 earnings have improved from $34.70 to $35.45 per share in the past 30 days, and estimates for 2027 earnings have improved from $42.67 to $44.23 per share over the same time frame.

LLY Estimate MovementImage Source: Zacks Investment Research

Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

© Pattanaphong Khuankaew / Getty Images

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not yet owned by Big Pharma. This scenario analysis examines who would actually benefit if a deal happens.

Why Viking Is the Most-Watched M&A Target Viking is a clinical-stage biotech with no revenue and a market cap near $3.59 billion. Shares closed at $30.89 on May 22, 2026, down 12.2% year to date. Analyst sentiment, however, is striking, with almost all analysts rating it Buy or Strong Buy, and a mean target price all the way up at $92.33.

The lead asset is doing the talking. Oral VK2735 delivered up to 12.2% weight loss at 13 weeks, with 80% of participants achieving at least 10% weight loss. Phase 3 VANQUISH-1 is fully enrolled with 4,500+ patients. Cash burn is accelerating: Q4 2025 net loss hit $157.66 million against roughly $706 million in cash, sharpening the strategic clock.

Existing Shareholders Benefit For current holders, the standalone case is the $92.33 analyst target, which assumes successful Phase 3 readouts. A deal would compress that timeline. Biotech buyouts of clinical-stage assets have historically closed well above prevailing prices, and recent obesity deals (notably Pfizer’s roughly $9.8 billion Metsera acquisition) set a reference point. Speculative buyout investing remains one of the highest-risk strategies in biotech: trial setbacks, regulatory delays, and deal breaks can all hit hard.

The Potential Buyer Benefits Eli Lilly (NYSE: LLY) already dominates the category. Q1 2026 revenue of roughly $19.8 billion grew 55.5%, with Mounjaro and Zepbound leading. A second platform still adds optionality, though antitrust optics complicate the fit at its $949.7 billion market cap.

Pfizer (NYSE: PFE) has been the most active acquirer in obesity. CEO Albert Bourla said, “2026 will be an important year rich in key catalysts, including our expectation for approximately 20 key pivotal study starts.” A Phase 3-ready dual agonist would integrate directly into the Metsera pipeline buildout.

Novo Nordisk (NYSE: NVO) is defending share. Shares are down 33.2% over the past year, and 2026 guidance calls for adjusted sales growth of −4% to −12%. A defensive bid is plausible.

Merck and Amgen round out the longer-shot list. Merck is underweight obesity and already acquiring Terns Pharmaceuticals, while Amgen has MariTide advancing internally, which may reduce urgency rather than create it.

Competitors and the Industry Benefit The clearest secondary winner is Structure Therapeutics (NASDAQ: GPCR), whose oral aleniglipron delivered 16.3% placebo-adjusted weight loss at 44 weeks. With a $2.8 billion market cap and a $106.47 average analyst target, Structure would inherit the scarcity premium if Viking is removed from the board. The Terns deal already shows Big Pharma’s willingness to consolidate metabolic assets.

For the broader industry, a Viking transaction would validate the tuck-in playbook, likely re-rate the obesity small-cap basket, and serve as an FTC test case for GLP-1 consolidation. It would also mark Polymarket as a usable M&A signal in biotech research.

The Bottom Line Even with 61.5% odds priced against a deal, Viking remains at the center of the obesity M&A conversation. If a transaction occurs, shareholders, the acquirer, and the broader obesity basket all stand to gain. Worth watching: Phase 3 enrollment updates, oral VK2735 progress, and any Big Pharma business development signaling through the rest of 2026.

Publication presented concurrently with oral presentation at
American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist

Publication and presentation detail dose-dependent, clinically meaningful and
statistically significant reductions in body weight with continued weight loss beyond 36 weeks,
up to 16.2% during the open-label extension

Aleniglipron safety profile reflects well-known GI-related GLP-1 class adverse events,
with favorable tolerability profile demonstrated by an overall low (10.4%) discontinuation rate

Phase 3 program remains on track to initiate in Q3 2026

Additional presentations related to Structure’s obesity pipeline, including amylin and combination data, expected at the American Diabetes Association’s 86th Scientific Sessions

SAN FRANCISCO, June 05, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced a publication in Nature Medicine detailing results from the Phase 2b ACCESS clinical trial of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity.

The Nature Medicine publication, titled, "Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial," can be accessed online at: https://www.nature.com/articles/s41591-026-04476-6. The publication was released concurrent with an oral presentation during the American Diabetes Association’s 86th Scientific Sessions by lead author, Julio Rosenstock, MD, Chair of the aleniglipron program Steering Committee and Clinical Professor of Medicine, University of Texas, Southwestern Medical Center.

The data highlights the efficacy from three maintenance dose levels in the core Phase 2b ACCESS study, as well as a predefined interim analysis of the open-label extension (OLE) safety study that demonstrated the durability of weight loss beyond 36 weeks, and improved tolerability from a lower 2.5 mg starting dose. The data from these studies provide support for the study design of the upcoming Phase 3 program which is expected to initiate in the third quarter of 2026.

“The data published today provide important new details around the previously reported reductions in body weight in patients dosed with aleniglipron. Interestingly, participants continued to lose weight after a median follow up of 20 weeks in the open label extension phase of the study after finalizing the 36 weeks in the double-blind treatment period, with no apparent weight loss plateau. This is an important distinction for a once-daily oral, non-peptide GLP-1 receptor agonist to potentially become an additional treatment option for patients,” stated Dr. Rosenstock, MD, Chair of the Steering Committee. “The study closely monitored the participant experience and additional impacts across key measures of tolerability, including the ability to restart or increase dosing titration after interruption without substantial increase in emesis events, which may be helpful for clinicians to gain a clinical perspective of treatment tolerance.”

Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for the treatment of obesity. As previously reported, at Week 36, each of the three doses in the ACCESS study achieved statistical significance on the primary endpoint and all key secondary endpoints. Other cardiovascular risk factors showed improvement with aleniglipron, such as systolic and diastolic blood pressure, hsCRP, waist circumference and HbA1c, which could positively contribute to the known cardiovascular benefits of approved GLP-1s. The interim analysis from the OLE study showed that patients continued to lose weight after a median follow up of 20 weeks, with weight loss of 13.3%, 16.2%, and 15.3% in the participants coming from 45 mg, 90 mg, and 120 mg aleniglipron arms from the double-blind treatment period, respectively.

As seen in prior studies, adverse events (AEs) in the patients treated with aleniglipron are similar to those seen in the GLP-1 class of medicines. Gastrointestinal (GI) events were generally mild to moderate and decreased in frequency over time and most patient discontinuations occurred during the initial titrations in dose.

There was no apparent dose-response relationship for the most common GI AEs across all aleniglipron treatment arms, and treatment discontinuations due to any treatment related adverse event (TEAE) were limited. The heat maps of dose levels overlaid with vomiting events add clarity to interpretation of the AE profile and add valuable insights into the participant experience on aleniglipron. Upon examination of each participant’s dosing across the study, it becomes clear that although some participants required dose interruptions or reductions, when the dose was re-initiated or up-titrated again, vomiting rarely recurred. This suggests that participants on aleniglipron may successfully restart treatment or continue to increase dosing after an interruption. This could potentially increase the likelihood to remain on treatment for extended periods of time, which is essential for a clinically meaningful treatment of obesity.

“We are pleased to have the ACCESS study data published in Nature Medicine to provide additional details about the important outcomes from this trial. We are on track to initiate our Phase 3 program of aleniglipron in the third quarter of 2026 with a starting dose of 2.5 mg and the intent to evaluate multiple doses based on this data and our End of Phase 2 meeting with the FDA,” said Blai Coll, M.D., Ph.D., Chief Medical Officer of Structure Therapeutics. “We are confident in the potential for once-daily oral aleniglipron to transform the treatment of obesity for patients around the world.”

In addition, Structure Therapeutics will have multiple other presentations related to its obesity pipeline, including amylin and combination data, at the ADA 86th Scientific Sessions. Details of the additional presentations are as follows:

Title: Exploring a Lower Starting Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials
Session: Late Breaking Poster Session (3101-LB)
Date: Sunday, June 7
Time: 12:30 p.m. – 1:30 p.m. CT

Title: Combination Treatment of Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron and Small Molecule Amylin Receptor Agonist ACCG-2671 Demonstrated Additional Weight Loss than Monotreatment in Obese NHPs
Session: Late Breaking Poster Session (3061-LB)
Date: Sunday, June 7
Time: 12:30 p.m. – 1:30 p.m. CT

Title: Comparison of Conditioned Taste Avoidance Profiles between GLP-1 Peptides, Amylin Peptides, and Small Molecule Amylin Receptor Agonists
Session: Late Breaking Poster Session (3062-LB)
Date: Sunday, June 7
Time: 12:30 p.m. – 1:30 p.m. CT

Title: Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial
Session: General Poster Session (2637-P)
Date: Monday, June 8
Time: 12:30 p.m. – 1:30 p.m. CT

Copies of these presentations will be made available on the Structure Therapeutics website at https://structuretx.com/publications/.

About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; the planned initiation of the aleniglipron Phase 3 study and the timing thereof; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron and any other of the Company’s investigational compounds; and any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials. In addition, when or if used in this press release, the words and phrases “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to topline results that the Company reports are based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; the preliminary nature of the results due to the length of the study and sample size and the results from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and completion of the Company’s planned Phase 3 clinical program and other clinical studies; the Company’s ability to advance aleniglipron, ACCG-2671, LTSE-2578, ACCG-3535, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company’s therapeutic candidates; competitive products or approaches limiting the commercial value of the Company’s product candidates; the Company’s ability to fund development activities and achieve development goals; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
[email protected]

Jun Yoon
Structure Therapeutics Inc.
[email protected]

Media:
Dan Budwick
1AB
[email protected]

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript